Results 71 to 80 of about 7,285,650 (306)

Cumulative incidence of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients with and without chronic graft-versus-host-disease.

open access: yes, 2017
Extensive chronic GVHD was associated with the development of TB (P = 0.003) There is a 4.89 ± 1.32% probability of having TB disease at 1000 days after allogeneic HSCT for extensive chronic GVHD and 1.42 ± 0.50% for limited or without chronic GVHD ...
Dong-Gun Lee (3826297)   +18 more
core   +1 more source

Silicone Breast Implants as a Model System for Understanding Polymer Permeation in Soft Materials In Vivo

open access: yesAdvanced Healthcare Materials, EarlyView.
Silicone breast implants are presented as a model system for understanding polymer permeation in vivo. Rather than representing material failure, “gel bleed” emerges from solution–diffusion transport‐mediated. By integrating polymer architecture, physicochemical transport, and biointerfacial processes, this review provides a unified framework that ...
D. Bouyer   +12 more
wiley   +1 more source

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis

open access: yesHaematologica, 2019
The use of antihuman T-lymphocyte immunoglobulin in the setting of transplantation from an HLA-matched related donor is still much debated. Acute and chronic graft-versus-host disease are the main causes of morbidity and mortality after allogeneic ...
Marie Robin   +26 more
doaj   +1 more source

Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin [PDF]

open access: yes, 1999
465-469Our unit performed transplantations on 21 classes II and III thalassaemic patients [class II patients had either hepatomegaly or portal fibrosis and class III patients had both]. We used busulfan [15 mg/kg] and cyclophosphamide [200 mg/kg].
Khojasteh, H.N.
core  

Progress in acute graft versus host disease

open access: yes, 2007
Purpose of review The aim of this article is to highlight both experimental and clinical studies contributing to our present understanding of acute graft versus host disease. Recent findings New cellular players and new molecules in induction, modulation
Holler, Ernst
core   +1 more source

Validation of Minnesota acute graft-versus-host disease Risk Score [PDF]

open access: yes, 2020
Using multicenter data, we developed a novel acute graft-versus-host disease Risk Score which more accurately predicts response to steroid treatment, survival and transplant related mortality than other published risk scores based upon clinical grading ...
Shernan G. Holtan   +5 more
core   +1 more source

Optical Detection of Cellular Signals at Material Interfaces

open access: yesAdvanced Healthcare Materials, EarlyView.
Emerging functional materials are transforming optical detection of cellular signals. This review highlights optical techniques that exploit the unique optical properties of diverse materials to detect and quantify cellular electrical, chemical, and mechanical signals, and discusses key opportunities and challenges.
Xuchen Ren   +5 more
wiley   +1 more source

Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy

open access: yesHaematologica, 2016
Due to the lack of specificity for tumor antigens, allogeneic T-cell therapy is associated with graft-versus-host disease. Enhancing the anti-tumor specificity while reducing the graft-versus-host disease risk of allogeneic T cells has remained a ...
Angelika Holler   +9 more
doaj   +1 more source

Selective allodepletion to improve anti-viral and anti-leukaemic responses after haploidentical transplantation [PDF]

open access: yes, 2009
Immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical SCT, but infection and leukaemic relapse remain problematic.
Samarasinghe, S, Samarasinghe, S.
core  

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy